YMAB Y-mAbs Therapeutics Inc.

29.17
+1.34  (+5%)
Previous Close 27.83
Open 28.3
Price To Book 5.83
Market Cap 1,159,702,764
Shares 39,756,694
Volume 281,561
Short Ratio
Av. Daily Volume 238,874
Stock charts supplied by TradingView

NewsSee all news

  1. Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

    NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

    NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  3. Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its 2019 financial and operating results on Thursday, March 12, 2020,

  4. Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

    NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  5. Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing completed March 31, 2020.
Naxitamab
Relapsed/Refractory High-Risk Neuroblastoma
Rolling BLA filing to be completed by early May 2020.
Omburtamab
CNS/Leptomeningeal Metastases from Neuroblastoma

Latest News

  1. Y-mAbs Announces Submission of Naxitamab Biologics License Application to U.S. FDA

    NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  2. Y-mAbs Announces 2019 Financial Results and Recent Corporate Developments

    NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  3. Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020

    NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its 2019 financial and operating results on Thursday, March 12, 2020,

  4. Y-mAbs Announces Positive Pre-BLA Meeting with FDA for Omburtamab

    NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  5. Y-mAbs Therapeutics To Present At 38th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  6. Y-mAbs Announces Positive Naxitamab Frontline Data

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  7. Y-mAbs and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for Omburtamab

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  8. Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

    NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  9. Y-mAbs Initiates Rolling Submission of Biologics License Application to U.S. FDA for Naxitamab for Treatment of Neuroblastoma

    NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  10. Y-mAbs Announces Update on Omburtamab in DSRCT

    NEW YORK, Nov. 15, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  11. Y-mAbs Announces Third Quarter 2019 Financial Results and Recent Corporate Developments

    NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  12. Y-mAbs to Announce Third Quarter 2019 Financial and Operating Results on November 13

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB) today announced that it will report its third quarter 2019 financial and operating results on Wednesday,

  13. Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of

  14. Y-mAbs Announces Naxitamab Update

    NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (NASDAQ:YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel,

  15. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current